To evaluate the capability of MIF of modulating resistance to cetuximab in CRC cells, cell proliferation rate was evaluated on sensitive GEO cells treated with cetuximab in the presence and absence of human recombinant MIF (hrMIF) at 100 ng/mL for 24 h. Here, MIF is linked to colorectal carcinoma.